You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy
|
|---|---|
| Published in |
Molecular Cancer, March 2014
|
| DOI | 10.1186/1476-4598-13-60 |
| Pubmed ID | |
| Authors |
Li-Sheng Chang, Chih-Hsiang Leng, Yi-Chen Yeh, Chiao-Chieh Wu, Hsin-Wei Chen, Hai-Mei Huang, Shih-Jen Liu |
| Abstract |
Although cytotoxic T lymphocytes (CTLs) play a major role in eradicating cancer cells during immunotherapy, the cancer-associated immunosuppressive microenvironment often limits the success of such therapies. Therefore, the simultaneous induction of cancer-specific CTLs and reversal of the immunosuppressive tumor microenvironment may be more effectively achieved through a single therapeutic vaccine. A recombinant lipoprotein with intrinsic Toll-like receptor 2 (TLR2) agonist activity containing a mutant form of E7 (E7m) and a bacterial lipid moiety (rlipo-E7m) has been demonstrated to induce robust CTL responses against small tumors. This treatment in combination with other TLR agonists is able to eliminate large tumors. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Chile | 1 | 2% |
| United States | 1 | 2% |
| South Africa | 1 | 2% |
| Unknown | 55 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 12 | 21% |
| Researcher | 12 | 21% |
| Student > Master | 6 | 10% |
| Student > Doctoral Student | 4 | 7% |
| Student > Bachelor | 4 | 7% |
| Other | 12 | 21% |
| Unknown | 8 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 17 | 29% |
| Biochemistry, Genetics and Molecular Biology | 10 | 17% |
| Immunology and Microbiology | 10 | 17% |
| Medicine and Dentistry | 3 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Other | 3 | 5% |
| Unknown | 13 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 March 2014.
All research outputs
#13,405,680
of 22,749,166 outputs
Outputs from Molecular Cancer
#829
of 1,717 outputs
Outputs of similar age
#109,946
of 223,385 outputs
Outputs of similar age from Molecular Cancer
#20
of 39 outputs
Altmetric has tracked 22,749,166 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,717 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 223,385 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.